Please login to the form below
testosterone
This page shows the latest testosterone news and features for those working in and with pharma, biotech and healthcare.
FDA approves Myovant’s oral pill Orgovyx for prostate cancer
In this study, Orgovyx achieved sustained testosterone suppression to castrate levels in 96.7% of patients from week five to week 48, in comparison to 88.8% for those receiving leuprolide ... It is designed to block the GnRH receptor, which in return
Latest news
-
Myovant preps US filing for relugolix in prostate cancer
A response in the trial was defined as achieving and maintaining testosterone suppression at castration levels over the course of the 48-week study, and relugolix cleared the 90% rate required ... The data also showed that relugolix was also more
-
Bayer preps filings for new prostate cancer drug
The new drug has a fairly benign safety profile, which is put down to the fact that it has minimal blood-brain barrier penetration and does not significantly increase testosterone levels
-
Bayer picks up PMEA award for multi-channel engagement
London. The work, delivered with support from digital agency Oi, provided a novel approach to restoring growth to Bayer’s established testosterone market leader Nebido.
-
Astellas’ Xtandi cancer drug rejected by NICE
cancer who have already had treatment to reduce testosterone and have had docetaxel chemotherapy.
-
Transition takes on Lilly muscle-boosting drug
Despite its effect on testosterone levels there was no accompanying increase in prostate specific antigen (PSA) levels. ... PSA levels are known to rise with testosterone replacement therapy (TRT) and there have been concerns TRT could activate or
More from news
Approximately 1 fully matching, plus 40 partially matching documents found.
Latest Intelligence
-
Reaching patients and HCPs during the pandemic
Clarus Therapeutics pushed through with the launch of its testosterone replacement tablet, Jatenzo, despite the disruption caused by COVID-19.
-
Case study: Tackle TD for Bayer UK
Client:Bayer UK. Agency:Virgo Health and Oi Ltd. Campaign:Tackle TD. Timescale:N/A. Testosterone deficiency affects around one million British men, but symptoms like fatigue are often ignored, and ... One million British men are estimated to have
-
Deal Watch April 2016
50 . Acerus (CA). Aytu (US). US license and commercialisation. Approved nasal testosterone for treatment of hypogonadism.
-
Deal Watch table for October 2014
130. TesoRx Pharma/Aspen. Licence [C]. For TSX 002 an unmodified oral testosterone replacement.
More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.
Latest appointments
-
Antares appoints David Bergstrom as SVP
The appointments come as the company looks to expand its business after the commercialisation of Otrexup (methotrexate) for arthritis and the advance in development of testosterone replacement therapy Vibex QS T.
-
Former Pfizer VP joins Antares
methotrexate) for arthritis and advance the development of testosterone replacement therapy Vibex QS T.
-
Galectin Therapuetics appoints Harold Shlevin as chief operating officer
Previously, he served as president and CEO of Solvay Pharmaceuticals, where he oversaw the successful launch of the first topical testosterone gel product in the US and he was co-founder
More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Scientific Strategy Lead, Medical Communications, UK
-
Highly competitive salary
- Senior Analyst, Market Access, UK, Home based
-
Highly competitive salary
- Vice President, Medical Communications, UK, six figure package
-
Six figure salary
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- New Omicron sub-variants cause COVID-19 cases to rise in the UK
- Sanofi Global Health unveils new nonprofit Impact brand
- Innovative Health Initiative launches first two calls for proposals to tackle ‘biggest’ health research challenges
- NHS App to revolutionise digital health and care with major digital updates by 2023
- Pfizer announces commitment to achieve Net-Zero Standard by 2040
- Novartis announces positive phase 3 trial results for advanced oesophageal cancer
- The Power of AI in Medical Education
- First evidence-based guide launched to put patients at heart of digital innovations
- FDA grants Priority Review for Biogen and Eisai’s lecanemab for early Alzheimer’s disease
- New Swiss research reveals how Omicron evades the immune system
- Evoke Kyne Named Communiqué Communications Consultancy of the Year 2021
- Michael Grela Elected President of the Society for Health Communication
- First evidence-based guide launched to put patients at heart of digital innovations
- Roche shares new positive Ocrevus data for MS patients
- FDA grants Priority Review for Biogen and Eisai’s lecanemab for early Alzheimer’s disease
- A creative awakening – how pharma is bringing innovation to the patient journey
- Country report: The healthcare market in South Korea
- European Commission approves potential new treatment for Pompe disease
PMHub
Envision Pharma Group
We are a global leader in the medical affairs space. Our purpose-built software and scientific solutions make us a unique...
Latest intelligence
- Five big changes in the healthcare comms landscape
- The world of healthcare has changed very greatly in the five years since The Difference Collective launched. Our agile model and talented team have enabled us to keep pace with...
- Early communications in Pharma: How effective pre-approval comms delivers launch success
- What communications are required for a successful launch...
- Our Top 5 Pharma Picks From Cannes Lions
- Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
